#ASCO22VR - Twitter Hashtag

over 4 years ago

My thoughts on the DETERMINATION trial in myeloma presented in the Plenary session of #ASCO22 and published simultaneously in @NEJM #ASCO22VR 1) This is not a trial of transplant vs no transplant. 2) It's ~ the 5th RCT of early vs delayed transplant

7

233

72

55

0

Vincent Rajkumar

@VincentRK

over 4 years ago

How I treat myeloma #ASCO22 edition algorithms. #ASCO22VR @MayoMyeloma More here: https://t.co/GvAPAQGzYH

5

138

49

37

0

Mike Thompson, MD, PhD, FASCO

@mtmdphd

over 4 years ago

#mmsm #ASCO22 #ASCO22VR #CARTcell

Vincent Rajkumar

@VincentRK

over 4 years ago

#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China #ASCO22 #ASCO22VR https://t.co/Mx6K5vZKqj

1

15

3

0

2

0

Vincent Rajkumar

@VincentRK

over 4 years ago

#1 Results of early versus delayed transplant strategy in the VRd and Len maintenance era. Long awaited results of DETERMINATION RCT to be presented as a plenary presentation. #ASCO22 #ASCO22VR @DanaFarber #PaulRichardson #NikhilMunshi https://t.co/nFccTPoY3k

2

16

5

1

0

Vincent Rajkumar

@VincentRK

over 4 years ago

#2 Risk of Progression of Smoldering Myeloma in African American patients is lower than white patients. Other studies show that outcomes in MM are related to access to good treatments. #ASCO22 #ASCO22VR @MalinHultcrantz @szusmani @DrOlaLandgren https://t.co/R6qeNiqkR6

1

18

4

1

0

Vincent Rajkumar

@VincentRK

over 4 years ago

#3 Important study that shows compared to other standard risk MM (hyperdiploid, trisomic MM), the t(11;14) subset of myeloma has more adverse outcomes. #ASCO22 #ASCO22VR @kaufman_MMdoc @SagarLonialMD @AjayNookaMD @WinshipAtEmory https://t.co/ErGKgtr4xJ

1

5

3

1

0

Vincent Rajkumar

@VincentRK

over 4 years ago

#4 CAR-T targeting GPRC5D. Doubt if one BCMA approach fails another BCMA approach will give significant benefit. These treatments are incredibly expensive. We need immunotherapy options that target something besides BCMA. @ZJU_China #ASCO22 #ASCO22VR https://t.co/Mx6K5vZKqj

1

15

3

0

Vincent Rajkumar

@VincentRK

over 4 years ago

#5 Risk adapted maintenance: Len for standard risk & Len plus Bortezomib for high risk gives outstanding results. #ASCO22 #ASCO22VR Clinically important & updated data are excellent. @RujulParikh @SagarLonialMD @AjayNookaMD @WinshipAtEmory https://t.co/Tn40rlyetP

1

17

10

4

0

Vincent Rajkumar

@VincentRK

over 4 years ago

Here are my Top 5 #ASCO22 @ASCO myeloma abstracts. #ASCO22VR Links to the full abstract. As in the past, I left out studies where similar results were already presented or published before. Top 5 based on new data, clinical impact & methodology Thread with countdown👇

3

86

28

16

0

Top Tweets for #ASCO22VR

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users